(Shutterstock) (Shutterstock)
Dry Eye syndrome

Israel’s BioLight Life Sciences has completed a successful US clinical study designed to assess the effectiveness of its multi-assay test in evaluating tears’ components of patients suffering from dry eye syndrome, and Israeli startup SoniVie has a novel system for the treatment of pulmonary arterial hypertension.

By: Michael Ordman



Diagnosing Dry Eye syndrome

Israel’s BioLight Life Sciences has completed a successful U.S. clinical study designed to assess the effectiveness of its TeaRx test evaluating tears’ components from patients suffering from dry eye syndrome (DES) as well as those of healthy subjects.

Treatment for Pulmonary Arterial Hypertension

Israeli startup SoniVie has a novel system for the treatment of pulmonary arterial hypertension, a progressive and fatal illness with no current cure. SoniVie has just successfully completed the first two procedures for its First In Human (FIH) multi-center clinical trial.

US approval for airway ventilation system

Israel’s Hospitech Respiration has received US FDA clearance for its AnapnoGuard 100 intubation system. AnapnoGuard is already CE2 cleared. More than 100 million patients annually require manual ventilation – the largest reason for admission into intensive care.

Diagnosing thyroid cancer

Israel’s Rosetta Genomics has announced that its RosettaGX Reveal diagnostic test for thyroid cancer is now approved for use in all 50 US states.

The potential to save millions of lives

Israel’s MobileODT demonstrated its life-saving smartphone technology to detect cervical cancer at the Innovation Showcase at this year’s AIPAC Conference. Launched only last May it has been used 6000 times in 20 countries.

How to cope with stress

Researchers at Tel Aviv University have developed tests to highlight the different rates people recover from stress. The study can help individuals to train themselves to relax. It also may lead to a blood test that can diagnose undue stress and help with the recovery process.

Preventing hospital readmissions

A study by Israel’s EarlySense has shown that the unresolved respiratory problems of heart patients was the most significant cause of their readmission to hospital. EarlySense’s “under the mattress” device monitors a patient’s breathing amongst many other factors.

New life for Gaza boy

13 year-old Mohammed Abu Jazer from Gaza got a new lease on life when surgeons from Israel’s voluntary humanitarian organization Save a Child’s Heart in Holon implanted an Israeli pulmonary valve. The Medronic Melody device will improve blood flow and help him avoid future surgeries.

One in four medical innovations has Israeli roots

Ruti Alon, co-chairman of this year’s IATI-Biomed Conference, highlighted that Israeli research is present in between 25% and 28% of the world’s successful biotech-based solutions. E.g. Exelon for Alzheimer’s, Doxil for cancer and Copaxone for Multiple Sclerosis.


Click here for all of this week’s Good News from Israel.